Page last updated: 2024-10-26

dipyridamole and EBV Infections

dipyridamole has been researched along with EBV Infections in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Thomé, MP1
Borde, C1
Larsen, AK1
Henriques, JAP1
Lenz, G1
Escargueil, AE1
Maréchal, V1

Other Studies

1 other study available for dipyridamole and EBV Infections

ArticleYear
Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation.
    Antiviral research, 2019, Volume: 172

    Topics: Antiviral Agents; B-Lymphocytes; Cell Line; Dipyridamole; DNA, Viral; Drug Repositioning; Epstein-Ba

2019